Levacetylleucine
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Neurofilament light chain (NfL) as a surrogate outcome measure for GM2 gangliosidoses.
Journal: Journal of neurology
Published: April 27, 2026
N-acetyl-L-leucine normalizes Transcription Factor EB activity by stereospecific bidirectional modulation in a HeLa cell model of Niemann-Pick disease type C.
Journal: PloS one
Published: March 20, 2026
Safety and efficacy of levacetylleucine in ataxia-telangiectasia: a phase 3, randomised, double-blind, placebo-controlled crossover trial.
Journal: The Lancet. Neurology
Published: March 15, 2026
Synthesis of N-Acetyl-D- and -L-Leucine-13C6 Tool Compounds in Neurodegenerative Disease.
Journal: ChemMedChem
Published: February 26, 2026
Arimoclomol and levacetylleucine for the treatment of neurologic manifestations of Niemann-Pick disease type C: A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG).
Journal: Genetics in medicine open
Published: September 29, 2025
Levacetylleucine (N-acetyl-l-leucine) for Niemann-Pick disease type C.
Journal: Trends in pharmacological sciences
Published: February 07, 2025
2024 FDA TIDES (Peptides and Oligonucleotides) Harvest.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: January 25, 2025
FDA approval of Miplyffa and Aqneursa: A dual breakthrough for the treatment of Neimann-Pick disease type C.
Journal: Alzheimer's & dementia (New York, N. Y.)
Published: November 09, 2024
Reply to "Levacetylleucine a game changer for Niemann-Pick disease type-C".
Journal: Brain & development
Published: October 29, 2024
Letter to the editor: "Levacetylleucine a game changer for Niemann pick disease type-C".
Journal: Brain & development
Published: October 11, 2024
Showing 1-12 of 12
Last Updated: 09/26/2026